Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Oncogen Pharma (Pvt) Limited

Private pharmaceutical manufacturer - oncology · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer focused on oncology products and operating under DRAP Drug Manufacturing Licence 000960.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence1 sourceCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Oncogen Pharma (Pvt.) Limited
Company type
Private pharmaceutical manufacturer - oncology
Address
WH-26 & WH-27-A3, Korangi Creek Industrial Park, Karachi, Pakistan
Corporate source details checked
16 Aug 2026
Corporate profile completeness
50%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000960 Oncogen Pharma (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000960 21 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx21public portfolio records represented
REG17unique registrations represented
IDX21indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR21current validated price records
G9generic molecules in indexed catalogue
DF4dosage-form groups
TA1therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage100%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage76%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixOncogen Pharma (Pvt) LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/oncogen-pharma-pvt-limitedGenerated 23 Sep 2026Oncology & immunology21 · 100%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioOncogen Pharma (Pvt) LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/oncogen-pharma-pvt-limitedGenerated 23 Sep 202621presentationsCapsule8 · 38%Infusion5 · 24%Tablet5 · 24%Injection3 · 14%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionOncogen Pharma (Pvt) LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/oncogen-pharma-pvt-limitedGenerated 23 Sep 202616comparable productsBelow peer median7 · 44%Near peer median6 · 38%Above peer median3 · 19%Company median price position-0.4%Lowest-price equivalents5Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsOncogen Pharma (Pvt) LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/oncogen-pharma-pvt-limitedGenerated 23 Sep 2026AJM Pharma (Pvt.) Limited8 shared89% overlapHimmel Pharmaceuticals Private Limi…7 shared78% overlapLab Diagnostic Systems (SMC) Pvt. L…7 shared78% overlapPharmasol (Pvt) Ltd.6 shared67% overlapCCL Pharmaceuticals (Pvt.) Limited4 shared44% overlapPharmedic Laboratories (Pvt.) Ltd L…4 shared44% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Oncology & immunology21 products · 100%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antineoplastic medicines21 products · 100%
Formulation footprint

Dosage forms

Capsule8 products
Infusion5 products
Tablet5 products
Injection3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 NilosignaNilotinib 5presentations 150 mg, 200 mg · Capsule #2 LemirylLenalidomide 3presentations 10 mg, 25 mg, 5 mg · Capsule #3 PacnogenPaclitaxel (albumin-bound nanoparticles) 3presentations 150 mg/25 mL, 30 mg/5 mL, 300 mg/50 mL · Infusion #4 DoxetranDoxorubicin 2presentations 10 mg/5 mL, 50 mg/25 mL · Injection #5 DoxiantDocetaxel 2presentations 20 mg, 80 mg/4 mL · Infusion #6 ImatiglivImatinib 2presentations 100 mg, 400 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median744% of comparable products
Near market median6within ±5% of median
Above market median319% of comparable products
Lowest-price equivalents5ties included
Company median price position -0.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Nilosigna 150 mgNilotinib · Capsule · 40's PKR 1,605.32/capsule-32.8% vs market median Nilosigna 200 mgNilotinib · Capsule · 28's PKR 2,140.40/capsule-31.4% vs market median Lemiryl 25 mgLenalidomide · Capsule · 21's PKR 1,292.51/capsule-22.8% vs market median Lemiryl 5 mgLenalidomide · Capsule · 21's PKR 334.03/capsule-22.8% vs market median Lemiryl 10 mgLenalidomide · Capsule · 21's PKR 586.78/capsule-22.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

AJM Pharma (Pvt.) Limited124 products · 61 generics 8shared generics Himmel Pharmaceuticals Private Limited62 products · 24 generics 7shared generics Lab Diagnostic Systems (SMC) Pvt. Ltd.42 products · 24 generics 7shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 6shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 4shared generics Pharmedic Laboratories (Pvt.) Ltd Lahore122 products · 70 generics 4shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers17Distinct registrations among indexed, published, presentation-validated products only
Verified price observations21
Products with a verified price21
Products with multiple price observations0
Source records with multiple versions21
Latest portfolio source check9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

17 unique registration(s) · 21 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Abytiga Abiraterone acetate 250 mg Tablet 120's 118215 PKR 202,094.93 PKR 1,684.12/tablet Near median
Cisrenza Cisplatin 50 mg/50 mL Injection 50mlx1's 135220 PKR 1,247.00 PKR 24.94/mL No comparator
Doxetran Doxorubicin 10 mg/5 mL Injection 1's 130730 PKR 763.54 PKR 763.54/vial/unit Near median
Doxetran Doxorubicin 50 mg/25 mL Injection 1's 130731 PKR 2,630.76 PKR 2,630.76/vial/unit 11% below median
Doxiant Docetaxel 20 mg Concentrate for solution for infusion 1's 128122 PKR 12,826.25 PKR 12,826.25/vial/unit No comparator
Doxiant Docetaxel 80 mg/4 mL Concentrate for solution for infusion 1's 128123 PKR 31,598.91 PKR 31,598.91/vial/unit 15% below median
Imatigliv Imatinib 100 mg Tablet 60's 118049 PKR 72,284.27 PKR 1,204.74/tablet 12% above median
Imatigliv Imatinib 400 mg Tablet 30's 123414 PKR 103,263.24 PKR 3,442.11/tablet Near median
Lemiryl Lenalidomide 5 mg Capsule 21's 120131 PKR 7,014.71 PKR 334.03/capsule 23% below median
Lemiryl Lenalidomide 10 mg Capsule 21's 120132 PKR 12,322.35 PKR 586.78/capsule 23% below median
Lemiryl Lenalidomide 25 mg Capsule 21's 120133 PKR 27,142.76 PKR 1,292.51/capsule 23% below median
Nilosigna Nilotinib 150 mg Capsule 40's 118047 PKR 64,212.89 PKR 1,605.32/capsule 33% below median
Nilosigna Nilotinib 150 mg Capsule 112's 118047 PKR 267,584.86 PKR 2,389.15/capsule Near median
Nilosigna Nilotinib 150 mg Capsule 120's 118047 PKR 286,698.49 PKR 2,389.15/capsule Near median
Nilosigna Nilotinib 200 mg Capsule 28's 118048 PKR 59,931.16 PKR 2,140.40/capsule 31% below median
Nilosigna Nilotinib 200 mg Capsule 112's 118048 PKR 356,780.47 PKR 3,185.54/capsule Near median
Pacnogen Paclitaxel (albumin-bound nanoparticles) 300 mg/50 mL Concentrate for solution for infusion 1's 128119 PKR 40,541.44 PKR 40,541.44/vial/unit No comparator
Pacnogen Paclitaxel (albumin-bound nanoparticles) 30 mg/5 mL Concentrate for solution for infusion 1's 128120 PKR 5,823.22 PKR 5,823.22/vial/unit No comparator
Pacnogen Paclitaxel (albumin-bound nanoparticles) 150 mg/25 mL Concentrate for solution for infusion 1's 128121 PKR 25,196.23 PKR 25,196.23/vial/unit No comparator
Pectibine Capecitabine 500 mg Tablet 120's 118214 PKR 43,886.88 PKR 365.72/tablet 6% above median
Pectibine Capecitabine 500 mg Tablet 10's 118214 PKR 4,262.71 PKR 426.27/tablet 23% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Oncogen Pharma (Pvt) Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/oncogen-pharma-pvt-limited/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.